Tetrabenazine, the only FDA-approved therapy for HD, seeks to alleviate disease symptoms but does not treat the actual problem: the gain of toxic function caused by mutant Htt. Recent studies suggest that transient neuronal knockdown of Htt mRNA can reverse disease progression without compromising normal cellular function in vivo. Here, HTT is linked to Huntington disease.